Pilot analysis reveals TP53 mutations and genomic alterations predict treatment resistance in DLBCL and HGBL, suggesting early CAR-T therapy may be necessary.
Key Points
Failure of chemoimmunotherapy strongly associated with concurrent loss-of-function TP53 mutations and genomic alterations, highlighting a critical risk factor.
Patients with DLBCL and HGBL exhibiting these mutations may require alternative therapies like CAR T-cell therapy for better outcomes.
Retrospective pilot analysis involved genomic profiling of patients treated with first-line chemoimmunotherapy, comparing relapsed and complete response groups.
Identification of dual molecular signatures at diagnosis is crucial for directing innovative treatment strategies and improving patient outcomes.